This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

World Health Organisation classification of acute myeloid leukaemia

Authoring team

WHO classification of AML includes:

  • Acute myeloid leukemia with recurrent genetic abnormalities which includes
    • AML with a translocation between chromosomes 8 and 21 [t(8;21)]*
    • AML with a translocation or inversion in chromosome 16 [inv(16) or t(16;16;)]*
    • acute promyelocytic leukemia (APL) which usually has translocation between chromosomes 15 and 17*
    • AML with a translocation between chromosomes 9 and 11 [t(9;11)]
    • AML with a translocation between chromosomes 6 and 9 [t(6;9)]
    • AML with a translocation or inversion in chromosome 3 [inv(3) or t(3;3;)]
    • AML(megakaryoblastic) with a translocation between chromosomes 1 and 22 [t(1;22)]
    • Provisional entity: AML with mutated NPM1
    • Provisional entity: AML with mutated CEBPA
  • Acute myeloid leukaemia with myelodysplasia-related changes
  • Therapy-related myeloid neoplasms
  • Acute myeloid leukaemia, not otherwise specified
    • AML with minimal differentiation
    • AML without maturation
    • AML with maturation
    • Acute myelomonocytic leukemia
    • Acute monoblastic/monocytic leukemia
    • Acute erythroid leukaemia
    • Pure erythroid leukaemia
    • Erythroleukemia, erythroid/myeloid
    • Acute megakaryoblastic leukemia
    • Acute basophilic leukemia
    • Acute panmyelosis with myelofibrosis

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.